Antirheumatic drugs have minor effect on preeclampsia risk

Antirheumatic drugs have minor effect on preeclampsia risk
The use of a disease-modifying antirheumatic drug during pregnancy is rare and is associated with a nonsignificant increase in the risk for preeclampsia in women with autoimmune disease, according to a study published in the November issue of Arthritis Care & Research.

(HealthDay)—The use of a disease-modifying antirheumatic drug (DMARD) during pregnancy is rare and is associated with a nonsignificant increase in the risk for preeclampsia in women with autoimmune disease, according to a study published in the November issue of Arthritis Care & Research.

Kristin Palmsten, of the Harvard School of Public Health in Boston, and associates compared the risk for among 44,786 British Columbia women with and without , who were past users (study drug dispensing before ) and continuous users (use before and during the first 20 gestational weeks). Risks were compared for users of DMARDs, corticosteroids, and nonsteroidal anti-inflammatory drugs (NSAIDs).

The researchers found that DMARDs were dispensed to 0.1 percent of women during pregnancy. For past users, the incidence of preeclampsia was 2.3 percent for DMARDs, 2.7 percent for corticosteroids, and 2.9 percent for NSAIDs. For continuous users, compared with past users, there was a nonsignificant increase in the relative risk of preeclampsia for DMARD users. The delivery year-adjusted relative risk was 2.02 for women with systemic lupus erythematosus (SLE) compared to those without autoimmune disease. Exclusion of antimalarials attenuated the DMARD results and, on restriction of the analysis to women with autoimmune disease, the delivery-year adjusted relative risk was 0.95 (95 percent confidence interval, 0.25 to 3.55).

"We observed a two-fold increased risk of preeclampsia among women with SLE and a nonsignificant increase in risk in DMARD users," the authors write. "The DMARD and preeclampsia association was attenuated when antimalarials were excluded and null when restricted to women with autoimmune disease, which suggests the association is likely due to greater autoimmune disease severity in DMARD users."

Several authors disclosed financial ties to the pharmaceutical industry.

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Women with lupus have a higher risk for preeclampsia

Oct 30, 2012

New research reports that women with systemic lupus erythematosus (SLE) have a two-fold increase in risk of preeclampsia—a dangerous condition in which pregnant women develop high blood pressure (hypertension) and protein ...

Recommended for you

Two expats die of MERS in Saudi commercial hub

8 hours ago

Two foreigners died of MERS in the Saudi city of Jeddah, the health ministry said Saturday, as fears rise over the spreading respiratory virus in the kingdom's commercial hub.

UAE reports 12 new cases of MERS

8 hours ago

Health authorities in the United Arab Emirates have announced 12 new cases of infection by the MERS coronavirus, but insisted the patients would be cured within two weeks.

Filipino tests negative for Middle East virus

20 hours ago

A Filipino nurse who tested positive for the Middle East virus has been found free of infection in a subsequent examination after he returned home, Philippine health officials said Saturday.

User comments